Cartilage-homing peptide conjugates and methods of use thereof

Abstract

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

1 - 115 . (canceled) 
     
     
         116 . A peptide active agent conjugate, the peptide active agent conjugate comprising:
 a) a peptide comprising a sequence that has at least 85% sequence identity to SEQ ID NO: 396 or a fragment thereof comprising at least 18 amino acid residues that has at least 85% sequence identity to SEQ ID NO: 396; and   b) an active agent, wherein the active agent is desciclesonide, kineret, a j anus kinase (JAK) inhibitor, tofacitinib, dasatinib, flunisolide, an interleukin-1 (IL-1) inhibitor, an interleukin-1 (IL-1) receptor antagonist, an interleukin-12 (IL-12) antagonist, fibroblast growth factor 18 (FGF-18), insulin-like growth factor 1 (IGF-1), transforming growth factor beta (TFG-ß), a cathepsin K inhibitor, an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome drug, or MCC950.   
     
     
         117 . The peptide active agent conjugate of  claim 116 , wherein the peptide comprises 4 or more cysteine residues. 
     
     
         118 . The peptide active agent conjugate of  claim 116 , wherein the peptide or the fragment thereof comprises three or more disulfide bridges formed between cysteine residues, wherein one of the disulfide bridges passes through a loop formed by two other disulfide bridges. 
     
     
         119 . The peptide active agent conjugate of  claim 116 , wherein the IL-1 receptor antagonist is canakinumab, rilonacept, or gevokizumab. 
     
     
         120 . The peptide active agent conjugate of  claim 116 , wherein the peptide or the fragment thereof comprises 5 to 12 basic residues. 
     
     
         121 . The peptide active agent conjugate of  claim 116 , wherein the peptide is SEQ ID NO: 396. 
     
     
         122 . The peptide active agent conjugate of  claim 116 , wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents are linked to the peptide. 
     
     
         123 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent by fusion of the active agent to the peptide at an N-terminus or a C-terminus of the peptide. 
     
     
         124 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent at an N-terminus, at the epsilon amine of an internal lysine residue, at the carboxylic acid of an aspartic acid or glutamic acid residue, or a C-terminus of the peptide by a linker. 
     
     
         125 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent at a non-natural amino acid present in the peptide, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid. 
     
     
         126 . The peptide active agent conjugate of claim  1 , wherein the peptide is linked to the active agent by a cleavable linker comprising a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase. 
     
     
         127 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent by a linker comprising an amide bond, an ester bond, a carbamate bond, a carbonate bond, a hydrazone bond, an oxime bond, a disulfide bond, a thioester bond, a thioether bond, a triazole, a carbon-carbon bond, or a carbon-nitrogen bond. 
     
     
         128 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent by a hydrolytically labile linker. 
     
     
         129 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent by a pH sensitive, reducible, glutathione-sensitive, or protease cleavable linker. 
     
     
         130 . The peptide active agent conjugate of  claim 116 , wherein the peptide is linked to the active agent by a stable linker. 
     
     
         131 . A pharmaceutical composition comprising the peptide active agent conjugate of  claim 116 , or a salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         132 . A method of imaging an organ or body region of a subject comprising administering to the subject a peptide active agent conjugate comprising:
 a) a peptide comprising a sequence that has at least 85% sequence identity to SEQ ID NO: 396 or a fragment thereof comprising at least 18 amino acid residues that has at least 85% sequence identity to SEQ ID NO: 396;   b) an active agent, wherein the active agent is desciclesonide, kineret, a j anus kinase (JAK) inhibitor, tofacitinib, dasatinib, flunisolide, an interleukin-1 (IL-1) inhibitor, an interleukin-1 (IL-1) receptor antagonist, an interleukin-12 (IL-12) antagonist, fibroblast growth factor 18 (FGF-18), insulin-like growth factor 1 (IGF-1), transforming growth factor beta (TFG-ß), a cathepsin K inhibitor, an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome drug, or MCC950; and   c) a detectable agent.   
     
     
         133 . The method of  claim 132 , wherein the detectable agent is a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, or a radionuclide chelator. 
     
     
         134 . The method of  claim 132 , further comprising detecting a cancer or diseased region, tissue, structure, or cell. 
     
     
         135 . The method of  claim 132 , further comprising performing surgery on the subject and removing the cancer or diseased region, the tissue, the structure, or the cell. 
     
     
         136 . A method of treating a cartilage or kidney disorder in a subject comprising administering to the subject a peptide active agent conjugate comprising:
 a) a peptide comprising a sequence that has at least 85% sequence identity to SEQ ID NO: 396 or a fragment thereof comprising at least 18 amino acid residues that has at least 85% sequence identity to SEQ ID NO: 396; and   b) an active agent, wherein the active agent is desciclesonide, kineret, a j anus kinase (JAK) inhibitor, tofacitinib, dasatinib, flunisolide, an interleukin-1 (IL-1) inhibitor, an interleukin-1 (IL-1) receptor antagonist, an interleukin-12 (IL-12) antagonist, fibroblast growth factor 18 (FGF-18), insulin-like growth factor 1 (IGF-1), transforming growth factor beta (TFG-ß), a cathepsin K inhibitor, an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome drug, or MCC950.   
     
     
         137 . The method of  claim 136 , wherein the disorder is lupus nephritis, rheumatoid arthritis, gout, ankylosing spondylitis, psoriatic arthritis, osteoarthritis, fibrosis, scleroderma, chronic kidney disease, diabetic nephropathy, renal fibrosis, acute kidney injury, or calcium pyrophosphate deposition disease. 
     
     
         138 . The method of  claim 136 , wherein upon administration to the subject the peptide active agent conjugate homes to a cartilage or a kidney of the subject. 
     
     
         139 . The method of  claim 136 , wherein upon administration to the subject, the peptide active agent conjugate homes to proximal tubules of a kidney. 
     
     
         140 . The method of  claim 136 , wherein the administering comprises administering by inhalation, intranasally, orally, topically, parenterally, intravenously, subcutaneously, intra-articularly, intramuscularly administration, intraperitoneally, dermally, transdermally, or a combination thereof.